Literature DB >> 25573088

A longitudinal study of CEACAM1 expression in melanoma disease progression.

Douglas Zippel1, Hani Barlev1, Rona Ortenberg2, Iris Barshack3, Jacob Schachter3, Gal Markel3.   

Abstract

The present study characterized the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) expression profile in a longitudinal study during melanoma progression, in lesions obtained from the same patients: a primary skin lesion, a lymph node and a distant metastasis. The present study is expected to increase our understanding of the expression patterns of CEACAM1 in melanoma development. We identified 20 patients who could be analyzed for CEACAM1 expression over the course of disease progression. The pathology blocks were cut, and two slides were generated for each specimen. One underwent standard hematoxylin and eosin (H&E) staining and a corresponding slide underwent immunohistochemical staining for the detection of CEACAM1. For 13 patients who were able to be followed up serially from primary lesion, lymph node and distant metastasis, a borderline significant increase in the staining of the membrane was noted (P=0.06). In contrast, there was no equivalent increase in cytoplasmic CEACAM1 in the same group of patients. For the cohort of 20 patients with primary and distant metastasis, a significant increase in the membrane staining was noted (P=0.026) and again, no equivalent significant increase in cytoplasmic staining was observed. We report that CEACAM1 expression increases along the course of disease development and progression of a patient. CEACAM1 represents a novel area of research which may have profound influence in future methods of harnessing cellular immunity to combat this disease. The results of the present study confirm that CEACAM1 is potentially an extremely useful target in arresting melanoma progression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25573088     DOI: 10.3892/or.2014.3703

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

Review 1.  CEACAM1: Expression and Role in Melanocyte Transformation.

Authors:  Gabriela Turcu; Roxana Ioana Nedelcu; Daniela Adriana Ion; Alice Brînzea; Mirela Daniela Cioplea; Lucia Beatrice Jilaveanu; Sabina Andrada Zurac
Journal:  Dis Markers       Date:  2016-08-24       Impact factor: 3.434

2.  EphA2 signaling is impacted by carcinoembryonic antigen cell adhesion molecule 1-L expression in colorectal cancer liver metastasis in a cell context-dependent manner.

Authors:  Azadeh Arabzadeh; Kevin McGregor; Valérie Breton; Lauren Van Der Kraak; Uri David Akavia; Celia M T Greenwood; Nicole Beauchemin
Journal:  Oncotarget       Date:  2017-11-01

3.  A liquid biopsy for bronchopulmonary/lung carcinoid diagnosis.

Authors:  Mark Kidd; Irvin M Modlin; Ignat Drozdov; Harry Aslanian; Lisa Bodei; Somer Matar; Kyung-Min Chung
Journal:  Oncotarget       Date:  2017-12-29

4.  SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells.

Authors:  Shira Ashkenazi; Rona Ortenberg; Michal Besser; Jacob Schachter; Gal Markel
Journal:  Oncotarget       Date:  2016-05-24

5.  The human antibody fragment DIATHIS1 specific for CEACAM1 enhances natural killer cell cytotoxicity against melanoma cell lines in vitro.

Authors:  Maria L Dupuis; Valentina Fiori; Alessandra Soriani; Biancamaria Ricci; Sabrina Dominici; Diego Moricoli; Alessandro Ascione; Angela Santoni; Mauro Magnani; Maurizio Cianfriglia
Journal:  J Immunother       Date:  2015 Nov-Dec       Impact factor: 4.456

6.  Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells.

Authors:  Karin Kfir-Elirachman; Rona Ortenberg; Bella Vizel; Michal J Besser; Iris Barshack; Jacob Schachter; Yael Nemlich; Gal Markel
Journal:  Neoplasia       Date:  2018-03-17       Impact factor: 5.715

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.